Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Michal, Bista"'
Autor:
Matthew A. Coelho, Etienne De Braekeleer, Mike Firth, Michal Bista, Sebastian Lukasiak, Maria Emanuela Cuomo, Benjamin J. M. Taylor
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Off-target editing remains a concern for therapeutic applications of CRISPR-Cas9. Here the authors present CRISPR GUARD, which uses very short non-cleaving gRNAs to prevent editing at off-target sites.
Externí odkaz:
https://doaj.org/article/5ca3e3c9d50c40859d3cc5b4b7665184
Autor:
Fernando Orden Rueda, Michal Bista, Matthew D. Newton, Anne U. Goeppert, M. Emanuela Cuomo, Euan Gordon, Felix Kröner, Jon A. Read, Jonathan D. Wrigley, David Rueda, Benjamin J. M. Taylor
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
CRISPR-Cas9 systems are being continually improved to enhance specificity and improve functionality. Here the authors design hybrid DNA-RNA guide and tracr molecules to direct Cas9 nuclease activity with reduced off-target effects.
Externí odkaz:
https://doaj.org/article/c46a36e939634bf2b4da5347a251be8a
Autor:
Jeffrey W. Johannes, Fiona Pachl, Amber Balazs, Tieguang Yao, C. Larner, Lisa McWilliams, Marianne Schimpl, Scott W. Martin, Kevin J. Embrey, Tom D. Heightman, Paul Hemsley, Jonathan P. Orme, Derek Barratt, Giuditta Illuzzi, Andrew Madin, Paolo Di Fruscia, Avipsa Ghosh, Martin J. Packer, Scott D. Edmondson, Elisabetta Leo, Xiaolan Zheng, Matthew D. Chuba, Xiaohui Pei, Mark J. O'Connor, Verity Talbot, Ke Zhang, Stephen Fawell, Elizabeth Underwood, Anna Staniszewska, Lina Liu, Lin Xue, Sonja J. Gill, Anders Gunnarsson, Andrew Pike, Susan E. Critchlow, Jeffrey G. Varnes, Andrew X. Zhang, Sébastien L. Degorce, J. Lane, Sudhir M. Hande, Hongyao She, Sabina Cosulich, Michal Bista
Publikováno v:
Journal of Medicinal Chemistry. 64:14498-14512
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d5da59f02fe0bf1798c2492422c31c3
https://doi.org/10.1021/acs.jmedchem.1c01012
https://doi.org/10.1021/acs.jmedchem.1c01012
Autor:
J Willem M Nissink, Michal Bista, Jason Breed, Nikki Carter, Kevin Embrey, Jonathan Read, Jon J Winter-Holt
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151154 (2016)
MTH1 (NUDT1) is an oncologic target involved in the prevention of DNA damage. We investigate the way MTH1 recognises its substrates and present substrate-bound structures of MTH1 for 8-oxo-dGTP and 8-oxo-rATP as examples of novel strong and weak bind
Externí odkaz:
https://doaj.org/article/9fb8b358bc4f48ecb81ceedb4cb0f8a9
Autor:
Darren Cross, Matthew J. Martin, Carine M. Guérot, Nicolas Floc'h, Clare Gregson, Jonathan P. Orme, Michal Bista, Lin Xue, Xu Li, Amar Rahi, Xiliang Zhao, Richard A. Ward, L. Evans, Gail L. Wrigley, Arash Mosallanejad, Tieguang Yao, Claire McWhirter, David J. Hargreaves, Nicola Colclough, Sue Bickerton, Darren Mckerrecher, Peter Barton, Yang Ye, Yi Liu, Marta Wylot, M. Raymond V. Finlay, Xiaoming Kang, Eva M. Lenz, Daniel O'Neill, Verity Talbot, Olivier Lorthioir, Paul D. Smith
Publikováno v:
Journal of medicinal chemistry. 64(18)
The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including osimertinib, have been approved for cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58199c545ee296c2c44cec7db12bfba5
https://pubmed.ncbi.nlm.nih.gov/34491761
https://pubmed.ncbi.nlm.nih.gov/34491761
Autor:
Liz Flavell, Jakub Luptak, David J. Hargreaves, Steven L. Kazmirski, Tina Howard, Kate F. Wickson, Ning Gao, David I Fisher, Michal Bista, Philip B. Rawlins
Publikováno v:
Acta Crystallographica. Section D, Structural Biology
Mcl-1 is an important cancer target for drug therapy, through which normal apoptosis may be restored by inhibiting its protective function. An scFv and a Fab have been used to generate an apo Mcl-1 crystal system that is amenable to iterative structu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60f1ff2f5c281e68c59c2e4b03cee5ac
http://europepmc.org/articles/PMC6834078
http://europepmc.org/articles/PMC6834078
Autor:
Verity Talbot, Nancy Dekki, Joseph Shaw, Michal Bista, Michael Dabrowski, Lindsey Leach, Martin J. Main, Davide Gianni, Ian L. Dale, Ana J. Narvaez, Paul Hemsley, Jonathan P. Orme, Daniel Martinez Molina
Publikováno v:
Slas Discovery
Methods to measure cellular target engagement are increasingly being used in early drug discovery. The Cellular Thermal Shift Assay (CETSA) is one such method. CETSA can investigate target engagement by measuring changes in protein thermal stability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213f4a5b2c44e6340f38c4888400cd2a
https://doi.org/10.1177/2472555218813332
https://doi.org/10.1177/2472555218813332
Autor:
Benjamin J. M. Taylor, Michal Bista, Mike Firth, Matthew A. Coelho, Sebastian Lukasiak, Maria Emanuela Cuomo, Etienne De Braekeleer
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
Precise genome editing using CRISPR-Cas9 is a promising therapeutic avenue for genetic diseases, although off-target editing remains a significant safety concern. Guide RNAs shorter than 16 nucleotides in length effectively recruit Cas9 to complement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e97c8c9cc72e513b7fad69f6242aa1
https://doi.org/10.1038/s41467-020-17952-5
https://doi.org/10.1038/s41467-020-17952-5
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists.
Autor:
David Koes, Kareem Khoury, Yijun Huang, Wei Wang, Michal Bista, Grzegorz M Popowicz, Siglinde Wolf, Tad A Holak, Alexander Dömling, Carlos J Camacho
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32839 (2012)
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput screening,
Externí odkaz:
https://doaj.org/article/bfa426538b5d4582a9e9ca13d85e2907
Autor:
Michal Bista, David Smithson, Aleksandra Pecak, Gabriella Salinas, Katarzyna Pustelny, Jaeki Min, Artur Pirog, Kristin Finch, Michal Zdzalik, Brett Waddell, Benedykt Wladyka, Sylwia Kedracka-Krok, Michael A Dyer, Grzegorz Dubin, R Kiplin Guy
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e37518 (2012)
SJ-172550 (1) was previously discovered in a biochemical high throughput screen for inhibitors of the interaction of MDMX and p53 and characterized as a reversible inhibitor (J. Biol. Chem. 2010; 285:10786). Further study of the biochemical mode of a
Externí odkaz:
https://doaj.org/article/50c3d2a731444c08bd0b42fc618a17eb